Cannabinoid (CB1) receptors are the initial site of action for the primary psychoactive ingredient of the most commonly abused street drug, marijuana. In addition, activation of the CB1 receptor augments addictive effects of cocaine and heroin and the development of opioid dependence. The goal of this proposal is to elucidate the functional features of the CB1 receptor that may define mechanisms of drug-receptor interactions relevant to drug, abuse. We have already made progress identifying some of the structural and concomitant functional features of the CB1 receptor molecules. We propose to specifically characterize the regions in the CB1 receptor (motifs) involved in ligand recognition, activation and desensitization. Activation, in the context of this proposal, is the drug-induced alteration of receptor structure that allows interaction with signal transducing G-proteins. Desensitization is a mechanism of modulating the extent of receptor response and may be important in the development of tolerance to the cognate drug.
The first aim i s to more precisely define the structural features of C1, that lead to differential ligand recognition.
The second aim tests the hypothesis that different ligands trigger one of multiple conformational states of the receptor, each of which activate different G protein signaling pathways. As a complementary approach to defining the critical structural features of the receptor, we will correlate naturally occurring mutations (polymorphisms) in the CB1 receptor with specific changes in funtion. Natural mutations of other Gprotein coupled receptors have previously been shown to alter receptor and to cause disease.
The third aim tests the hypothesis that specific cannabinoid compounds differentially slesensitize the CB1 receptor response. This may be a mechanism for the production of the distinct pharmacological responses we have observed for these compounds. The consequences of CB1 receptor mutation may be altered neurological functions including predisposition to addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA009978-06A2
Application #
6546860
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Colvis, Christine
Project Start
1996-09-30
Project End
2007-04-30
Budget Start
2002-08-01
Budget End
2003-04-30
Support Year
6
Fiscal Year
2002
Total Cost
$194,625
Indirect Cost
Name
California Pacific Medical Center Research Institute
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94107
Soroceanu, Liliana; Murase, Ryuichi; Limbad, Chandani et al. (2013) Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 73:1559-69
McAllister, Sean D; Murase, Ryuichi; Christian, Rigel T et al. (2011) Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129:37-47
Zhao, Pingwei; Leonoudakis, Dmitri; Abood, Mary E et al. (2010) Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology 58:551-8
Scotter, Emma L; Abood, Mary E; Glass, Michelle (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:480-98
Marcu, Jahan P; Christian, Rigel T; Lau, Darryl et al. (2010) Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9:180-9
Kapur, Ankur; Samaniego, Patrick; Thakur, Ganesh A et al. (2008) Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther 325:341-8
Gehani, Neal C; Nalwalk, Julia W; Razdan, Raj K et al. (2007) Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain 8:850-60
McAllister, Sean D; Christian, Rigel T; Horowitz, Maxx P et al. (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6:2921-7
Anavi-Goffer, Sharon; Fleischer, Daniel; Hurst, Dow P et al. (2007) Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem 282:25100-13
Kapur, Ankur; Hurst, Dow P; Fleischer, Daniel et al. (2007) Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71:1512-24

Showing the most recent 10 out of 27 publications